

**Red Capital Strengthens “Red No.1 Healthcare Investment Limited Partnership” with
Strategic Investment from Government-Backed SME Support, Japan
to Accelerate Fund Expansion and Ecosystem Development**

Red Capital Co., Ltd. (Headquarters: Shibuya-ku, Tokyo) announces that it established the “Red No.1 Healthcare Investment Limited Partnership” (hereinafter, the “Red No.1 Fund”), a fund dedicated to the life sciences and healthcare sectors, and has since welcomed new investors, government-backed SME Support, Japan.

As a result of these new commitments, SME Support, Japan; Seibu Shinkin Bank; Academic Startup Acceleration L.P. (managed by UTokyo Innovation Platform Co., Ltd.); and The Shizuoka Bank, Ltd. have joined the Red No.1 Fund as limited partners. The Fund will continue its fundraising activities with a target fund size of JPY 6.0 billion.

■ Background and Vision of the Fund

Under its vision of “Evolving Humanity to the Next Stage,” Red Capital established the Red No.1 Fund to translate science and technology in the life sciences and healthcare sectors into real-world impact. While deep tech has the potential to generate significant societal value, it typically requires long development timelines and substantial capital, and in Japan, the availability of risk capital and support systems to sustain such growth remains insufficient.

The Red No.1 Fund combines two investment strategies: a “Seed-Driven” approach that provides continuous support from the seed stage through exit, and an “Ecosystem Complementary” approach that promotes sustained growth through secondary investments. Going beyond the provision of capital, the Fund delivers tailored, long-term support aligned with each company’s stage of development.

Furthermore, by identifying and nurturing promising technological seeds across regions, Red Capital seeks to contribute to the creation of new industries and the revitalization of local economies. Through an integrated approach encompassing investment, hands-on support, and ecosystem collaboration, Red Capital aims to achieve both financial returns and meaningful societal impact. Realizing the potential of science and technology as tangible businesses and delivering their value to society lies at the core of Red Capital’s mission.

■ Strategic Synergies with Limited Partners and Future Outlook

With the participation of SME Support, Japan, Red Capital expects to further accelerate cross-regional collaboration and the creation of new business opportunities by leveraging the organization's nationwide incubation facilities and extensive network. In addition, through collaboration with its acceleration programs, Red Capital will further enhance support for startup growth and expedite the path from development to commercialization and market entry.

Building on this collaborative foundation, the Red No.1 Fund will continue to expand its investment activities while strengthening the value creation capacity of the broader ecosystem. The Fund will also continue its fundraising efforts toward a target fund size of JPY 6.0 billion, with the aim of accelerating the social implementation of a greater number of innovative technologies.

■ Fund Overview

Name: Red No.1 Healthcare Investment Limited Partnership

Management Company: Red Capital Co., Ltd.

Fund Term: June 2025 – June 2037 (with a possible extension of up to three years)

Target Fund Size: JPY 6.0 billion

Investment Focus: Deep-tech startups in biotechnology, medical devices, and digital health

Investment Strategy: Primary and secondary investments

<For Inquiry regarding this matter>

Red Capital Co., Ltd.

info@redcapital.vc